(1-aminomethyl-3-methyl-cyclohexyl)-acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1-aminomethyl-3-methyl-cyclohexyl)-acetic acid
• 英文别名: PD 167345；1-aminomethyl-1-(3-methylcyclohexane) acetic acid；3-methylgabapentin；(1-aminomethyl-3-methylcyclohexane)acetic acid；3-Methyl-gabapentin；2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: UOPIILYKLVDKTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Prodrugs of GABA analogs, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20060229361A1

  公开（公告）日：2006-10-12

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，GABA类似物前药的药物组合物以及制备GABA类似物前药的方法。本发明还提供了使用GABA类似物前药的方法以及使用GABA类似物前药的药物组合物治疗或预防常见疾病和/或疾病的方法。
• Method of treating cartilage damage
  申请人：——

  公开号：US20020072533A1

  公开（公告）日：2002-06-13

  The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及通过给予类似GABA的类似物，例如Formula1的化合物及其药学上可接受的盐，来预防或治疗软骨损伤的方法，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating tinnitus
  申请人：——

  公开号：US20030176504A1

  公开（公告）日：2003-09-18

  The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  这项发明涉及通过给予α2δ配体治疗耳鸣的方法，例如，给予一种符合化学式1的化合物及其药用盐，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
  申请人：——

  公开号：US20030083382A1

  公开（公告）日：2003-05-01

  The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.

  本发明提供了加巴喷丁及其他GABA类似物的前药的延长释放口服剂型，这些剂型表现出较低的毒性。这些剂型特别适用于给予那些被代谢形成醛类物质的加巴喷丁及其他GABA类似物的前药。本发明的剂型适用于治疗或预防已知父体加巴喷丁或其他GABA类似物在治疗上有效的疾病和/或疾病。
• Method of treating attention deficit hyperactivity disorder
  申请人：——

  公开号：US20040006073A1

  公开（公告）日：2004-01-08

  This invention relates to a method of treating ADHD by administering an alpha2delta ligand such as, for example, gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof.

  这项发明涉及通过给予α2δ配体（例如加巴喷丁或普雷加巴林或其药用盐）来治疗注意力缺陷多动障碍的方法。